$16.20
00.00%
Pre-Market: Jul 19, 5:07 PM EDT
15 minutes delayed
Comments
Loading...
Avadel Pharmaceuticals
AVDLNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Avadel Pharmaceuticals (NASDAQ:AVDL) Stock, Analyst Ratings, Price Targets, Forecasts
Avadel Pharmaceuticals PLC has a consensus price target of $21 based on the ratings of 10 analysts. The high is $29 issued by Oppenheimer on March 5, 2024. The low is $11 issued by Jefferies on November 30, 2022. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Craig-Hallum on May 9, 2024, respectively. With an average price target of $24 between Needham, HC Wainwright & Co., and Craig-Hallum, there's an implied 48.15% upside for Avadel Pharmaceuticals PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Craig-Hallum
Piper Sandler
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Avadel Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/09/2024 | Buy Now | 35.8% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 66.67% | HC Wainwright & Co. | Oren Livnat | $25 → $27 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 41.98% | Craig-Hallum | Chase Knickerbocker | $22 → $23 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 35.8% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 35.8% | Needham | Ami Fadia | → $22 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2024 | Buy Now | 35.8% | Craig-Hallum | Chase Knickerbocker | $20 → $22 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 41.98% | Piper Sandler | David Amsellem | $18 → $23 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 79.01% | Oppenheimer | Francois Brisebois | $27 → $29 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | 54.32% | HC Wainwright & Co. | Oren Livnat | $21 → $25 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | 35.8% | Needham | Ami Fadia | $20 → $22 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | 29.63% | UBS | Ashwani Verma | → $21 | Initiates | → Buy | Get Alert |
| 12/20/2023 | Buy Now | 23.46% | Needham | Ami Fadia | $19 → $20 | Maintains | Buy | Get Alert |
| 11/09/2023 | Buy Now | 17.28% | Needham | Ami Fadia | $18 → $19 | Maintains | Buy | Get Alert |
| 10/04/2023 | Buy Now | 11.11% | Needham | Ami Fadia | → $18 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | Buy Now | 11.11% | Needham | Ami Fadia | → $18 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 11.11% | Piper Sandler | David Amsellem | $13 → $18 | Maintains | Overweight | Get Alert |
| 08/10/2023 | Buy Now | 11.11% | Needham | Ami Fadia | → $18 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 29.63% | HC Wainwright & Co. | Oren Livnat | → $21 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 11.11% | Needham | Ami Fadia | → $18 | Reiterates | → Buy | Get Alert |
| 07/05/2023 | Buy Now | 29.63% | HC Wainwright & Co. | Oren Livnat | $17.5 → $21 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | Buy Now | 54.32% | Oppenheimer | Francois Brisebois | $22 → $25 | Maintains | Market Outperform | Get Alert |
| 06/30/2023 | Buy Now | 11.11% | Needham | Ami Fadia | → $18 | Reiterates | Buy → Buy | Get Alert |
| 06/12/2023 | Buy Now | 35.8% | Oppenheimer | Francois Brisebois | → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 05/30/2023 | Buy Now | 11.11% | Needham | Ami Fadia | $14 → $18 | Reiterates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | 60.49% | LifeSci Capital | Patrick Dolezal | $17 → $26 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | -1.23% | Ladenburg Thalmann | Matthew Kaplan | $14.5 → $16 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | 35.8% | Oppenheimer | Francois Brisebois | $20 → $22 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | 8.02% | HC Wainwright & Co. | Oren Livnat | $14 → $17.5 | Maintains | Buy | Get Alert |
| 05/02/2023 | Buy Now | -13.58% | Needham | Ami Fadia | $12 → $14 | Maintains | Buy | Get Alert |
| 04/28/2023 | Buy Now | -25.93% | Needham | Ami Fadia | → $12 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | -32.1% | Needham | Ami Fadia | → $11 | Maintains | Buy | Get Alert |
| 04/03/2023 | Buy Now | 23.46% | Oppenheimer | Francois Brisebois | → $20 | Reiterates | → Outperform | Get Alert |
| 04/03/2023 | Buy Now | -32.1% | Needham | Ami Fadia | → $11 | Reiterates | → Buy | Get Alert |
| 03/23/2023 | Buy Now | -13.58% | HC Wainwright & Co. | Oren Livnat | $13 → $14 | Maintains | Buy | Get Alert |
| 02/27/2023 | Buy Now | 23.46% | Oppenheimer | Francois Brisebois | $19 → $20 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | -32.1% | Needham | Ami Fadia | → $11 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | -19.75% | HC Wainwright & Co. | Oren Livnat | → $13 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | Buy Now | -32.1% | Needham | Ami Fadia | → $11 | Reiterates | → Buy | Get Alert |
| 11/30/2022 | Buy Now | -32.1% | Jefferies | Chris Howerton | $6.5 → $11 | Upgrade | Hold → Buy | Get Alert |
| 11/21/2022 | Buy Now | -44.44% | Needham | Ami Fadia | $8 → $9 | Maintains | Buy | Get Alert |
| 08/11/2022 | Buy Now | -25.93% | SVB Leerink | Marc Goodman | $6 → $12 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | -44.44% | Needham | Ami Fadia | $6 → $9 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | -50.62% | Jefferies | Chris Howerton | $6 → $8 | Downgrade | Buy → Hold | Get Alert |
| 05/31/2022 | Buy Now | -62.96% | Needham | Ami Fadia | $14 → $6 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | -19.75% | HC Wainwright & Co. | Oren Livnat | $17 → $13 | Maintains | Buy | Get Alert |
| 05/27/2022 | Buy Now | -62.96% | SVB Leerink | Marc Goodman | $18 → $6 | Maintains | Outperform | Get Alert |
| 01/11/2022 | Buy Now | -7.41% | Needham | Ami Fadia | $16 → $15 | Maintains | Buy | Get Alert |
| 09/23/2021 | Buy Now | 4.94% | Needham | Ami Fadia | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Avadel Pharmaceuticals (AVDL) stock?
The latest price target for Avadel Pharmaceuticals (NASDAQ:AVDL) was reported by Needham on May 9, 2024. The analyst firm set a price target for $22.00 expecting AVDL to rise to within 12 months (a possible 35.80% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Avadel Pharmaceuticals (AVDL)?
The latest analyst rating for Avadel Pharmaceuticals (NASDAQ:AVDL) was provided by Needham, and Avadel Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Avadel Pharmaceuticals (AVDL)?
The last upgrade for Avadel Pharmaceuticals PLC happened on November 30, 2022 when Jefferies raised their price target to $11. Jefferies previously had a hold for Avadel Pharmaceuticals PLC.
When was the last downgrade for Avadel Pharmaceuticals (AVDL)?
The last downgrade for Avadel Pharmaceuticals PLC happened on August 10, 2022 when Jefferies changed their price target from $6 to $8 for Avadel Pharmaceuticals PLC.
When is the next analyst rating going to be posted or updated for Avadel Pharmaceuticals (AVDL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avadel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avadel Pharmaceuticals was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.
Is the Analyst Rating Avadel Pharmaceuticals (AVDL) correct?
While ratings are subjective and will change, the latest Avadel Pharmaceuticals (AVDL) rating was a reiterated with a price target of $22.00 to $22.00. The current price Avadel Pharmaceuticals (AVDL) is trading at is $16.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.